Not applicableAvailableNCT06443944
What this trial is testing
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Who this might be right for
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic Cancer+1 more
CG Oncology, Inc.